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over the time horizon of a patient’s lifetime were estimated at 20285, 144194, 299279, 
251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and 
CinnoVex, respectively. As a result, the incremental cost per QALY for patients 
receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 
and 1010429 USD, respectively, when compared with symptom management. The 
results were sensitive to changes in time horizon, disease progression and drug 
costs. ConClusions: DMDs in RRMS patients is associated with increased benefits 
compared with symptom management, albeit at higher costs. Because patients 
receiving Avonex incurred slightly higher QALYs than patients receiving other 
DMDs, treatment with Avonex dominate other DMDs in Iran.
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objeCtives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients’ quality of life. The aim of this study is to conduct a cost-utility 
analysis of natalizumab (Tysabri®) versus interferon beta-1a 44 mcg (Rebif®) – a 
commonly prescribed 1st line disease modifying therapy – in rapidly evolving severe 
relapsing-remitting MS patients from the Brazilian Public Healthcare System (SUS) 
perspective. Methods: A Markov model with 20-year time horizon with health 
states based on Expanded Disability Status Scale (EDSS) and disease relapses 
was developed. Since there are no published data evaluating long-term course 
specifically in RESRRMS, it was assumed transition probabilities on EDSS states were 
based on natural history studies in unselected RRMS patients, and relapse prob-
abilities based on a post-hoc analysis of the placebo patients on pivotal natalizumab 
AFFIRM trial. In each monthly cycle, patients can discontinue treatment, remain 
stable, progress to higher EDSS state, experience progressive multifocal leukoen-
cephalopathy (PML) or die. For natalizumab, we assumed efficacy data on disabil-
ity progression and relapse from AFFIRM trial and for interferon beta-1a 44 mcg 
we assumed efficacy data on disability progression and relapse from pivotal trial 
PRISMS. Patients with EDSS score ≥ 7.5 receive best supportive care. Resource use 
and costs were validated by an expert panel and valued using Brazilian public offi-
cial lists (DATASUS and BPS). Costs and outcomes were discounted (5%). Probabilistic 
sensitivity analyses covered variability in efficacy and costs. Results: The use of 
natalizumab was associated with slower EDSS progression and reduced relapse 
burden. The quality-adjusted life years obtained with natalizumab and interferon 
beta-1a 44 mcg were 9.27 and 8.75, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus interferon beta-1a 
44 mcg. ConClusions: For a patient with HARRMS, the model shows that natali-
zumab was dominant when compared to interferon beta-1a 44 mcg in the Brazilian 
Public Healthcare System.
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objeCtives: To estimate the costs associated with health and social care resource 
use in a UK cohort of people with progressive multiple sclerosis (MS). Methods: 
Health and social care resource use data were collected prospectively over 33 
months from a cohort of 458 patients with progressive MS enrolled in a UK clinical 
trial (the CUPID Trial). Resource use data are used in combination with unit costs 
(2011 costs) from published UK national sources, and estimates of costs/prices 
where required. Costs for informal (unpaid) care are estimated using equivalent 
hourly home care rates for UK NHS and social care services. Data are presented 
over the 33-month period of follow, and also to allow comparison with other 
studies, against an estimated 6-monthly cost. Regression analyses were used to 
explore the impact on cost estimates from explanatory variables. Results: The 
main component of resource us and costs was informal care provided by friends 
and family, accounting for over 84% of the estimated costs over time. Excluding 
informal care, the most important cost items, within the remaining sub-total of 
costs, were social care (52%), health care services (23%), medications (10%), adapta-
tions (8%), and hospitalisations (6%). From a Payer perspective, the estimated mean 
six-monthly costs of health and social care were £927, but from a broader perspec-
tive the estimated six-monthly cost was £10,737, when private and patient costs 
were included. Regression analyses identified disease severity, as characterised by 
the EDSS, as the main explanatory driver of cost estimates. ConClusions: This 
study presents new information to inform on the impact of progressive multiple 
sclerosis to add to the currently sparse evidence base. Data suggest that costs are 
considerable and fall mainly on patients and carers. The findings also confirm 
the central role of disability status in predicting overall costs associated with the 
impact of progressive MS.
NeUrologiCAl DisorDers – Patient-reported outcomes & Patient Preference 
studies
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reView of the literAtUre
Paz S., Comellas M., Lizán L.
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objeCtives: To appraise the literature relating adherence and other patients’ 
reported outcomes (PROs) to Multiple Sclerosis (MS) costs. Methods: Electronic 
databases [MedLine/PubMed, Google Scholar, Congress proceedings] were searched 
to identify publications analyzing MS costs related to adherence, persistence, sat-
times GDP per capita (43,000 EUR) in the Czech Republic. Results: Over a 20 year 
time-horizon, add-on lacosamide generated 11.47 QALYs and costs 33,439 EUR (per 
patient), whereas standard AEDs alone provided 11.09 QALYs and costs 22,916 EUR 
(per patient), respectively. The base-case ICER was calculated as 27,692 EUR/QALY. 
Based on the PSA and its cost-effectiveness acceptability curve (CEAC) we calculated 
that add-on lacosamide has a probability of cost-effectiveness at 43,000 EUR per 
QALY gained of 80.2% compared to standard AEDs alone. ConClusions: Based 
on data from clinical practice lacosamide as add-on treatment in patients with 
partial-onset seizures is cost-effective under the WTP threshold implicitly applied 
in the Czech Republic.
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objeCtives: Carbamazepine (CBZ) is a widely-used, first-line treatment in epilepsy. 
However, CBZ is associated with hypersensitivity adverse drug reactions (ADRs) 
ranging from mild rash such as maculopapular exanthema, to hypersensitivity 
syndrome, Steven-Johnson syndrome and toxic epidermal necrolysis (TEN). TEN is 
associated with a mortality rate of up to 30%. The presence of the HLA-A*3101 allele 
is associated with an increased risk of CBZ-induced hypersensitivity reactions [OR 
9.1, 95% CI, 4.0 to 20.7]. HLA-A*3101 is present in 2% - 5% of populations of Northern 
European descent. We aim to investigate the cost effectiveness of pharmacoge-
netic testing for HLA-A*3101prior to initiation of CBZ treatment in patient with 
epilepsy. Patients testing positive for the allele are prescribed an alternative antie-
pileptic drug, lamotrigine. Methods: A decision analytic model was developed to 
represent the first three months post initiation of anti-epileptic drug, to cover the 
period when the majority of severe ADRs manifest. A Markov model (cycle length 
1 year) was used to simulate costs (from the perspective of the NHS in the UK) and 
utilities incurred in subsequent years. This enables modelling of costs and disutili-
ties from long term sequelae of severe ADRs as well as the effectiveness of treatment 
in terms of remission of seizures. Transition probabilities, costs and utilities were 
sourced from patient level data from the SANAD trial [Lancet 369(9566):1000-15] 
and relevant literature. Results: Compared with no pharmacogenetic testing, and 
prescribing CBZ for all patients, the test results in an incremental cost effective-
ness ratio of £26,684 per QALY gained. The probability that testing is cost-effective 
at a threshold of £30,000 per QALY is 0.55, and the cost of preventing a single ADR 
is £35962. ConClusions: Pharmacogenetic testing for HLA-A*3101 prior to treat-
ment with CBZ might be cost-effective for populations of North European descent.
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objeCtives: Botulinum toxin type A (BoNT-A) is considered one of the treatments 
of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy 
(CP) patients, two years of age or older by decreasing hyperactivity and increasing 
muscle tone in patients. The aim was to compare the cost of Botox® (Allergan) and 
Dysport® (Ipsen), considering the administered dose per weight (U/kg) in child 
patients with equinus foot CP related. Methods: We performed an observational, 
longitudinal and retrospective study with data from clinical records from December 
1995 to October 2012. Records included patients younger than 18 years old with 
spasticity treated with BoNT-A at the Pediatric Neurology Service of the Hospital of 
La Paz (Madrid), with recorded birth and visit dates, weight and dose by muscle. Cost 
analysis only evaluated four muscle groups (pronator teres, adductor, semitendi-
nosus and triceps surae) including only direct costs (drug and visit costs). We used 
bootstrap as sensitivity analysis to assess the robustness of results. Costs were in 
euros 2013. Results: A total of 895 patients treated with BoNT-A for spasticity (543 
treated with Botox®, 292 with Dysport® and 60 with both) were included. Baseline 
characteristics and follow-up were similar in both groups. Patients had an average 
dose infiltrated per visit of 5.44 U/kg (SD 2.17) for Botox® and 14.73 U/kg (SD 5.26) 
for Dysport®, and average yearly visits of 3.71 for Botox® and 3.46 for Dysport®. The 
annual total cost per patient was 850 € for Botox® and 636 € for Dysport®. Of these 
total costs, annual visit costs of 362 € for Botox® and 347 € for Dysport®, and annual 
drug costs were 488 € for Botox® and 289 € for Dysport®. ConClusions: Based on 
the real-world management of pediatric spasticity patients with BoNT-A observed 
in our study, Dysport® could reduce annual total costs per patient.
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Cost-Utility ANAlysis of DiseAse-moDifyiNg DrUgs iN relAPsiNg-
remittiNg mUltiPle sClerosis iN irAN
Imani A., Golestani M., Tabrizi J.S., Janati A.
Tabriz Medical University, Tabriz, Iran
objeCtives: Disease-modifying drugs (DMDs) are a significant expenditure for 
treating multiple sclerosis. However, assessment of the cost-utility of DMDs com-
pared with symptom management in the presence of long-term data has been lim-
ited. To assess the lifetime cost-utility from the Iranian health care perspectives of 4 
disease-modifying drugs relative to symptom management alone in patients with 
relapsing-remitting multiple sclerosis using evidence from long-term published 
studies. Methods: A Markov model was developed with patients transitioning 
through health states based on Kurtzke expanded disability status scale (EDSS). 
Patient costs included drug costs, other medical and lost worker productivity costs. 
Patient quality of life was considered in the form of utilities. Costs were valued in 
2011 USD, and costs were discounted at 7.2%per annum. Various parameters and 
assumptions were tested in sensitivity analyses. Results: Total costs per patient 
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DyNAmiCs of QUAlity of life iN ChilDreN with CystiC fibrosis AgeD 
5-16 yeArs
Simonova O., Gorinova Y., Vinyarskaya I., Samsonova M., Chernikov V.
FSBI Scientific Center of Children’s Health, RAMS, Moscow, Russia
objeCtives: For improvement of aiding effectiveness both for clinicians and spe-
cialists in the field of health care system one should know quality of patient’s life 
in different time period rating of the disease. Methods: 70 cystic fibrosis (CF) 
children from Russia and CIS countries 5-16 years were interviewed using HUI ver-
sion 15Q, while children over 12 years responded on their own (self assessment), 
information about children younger 12 years was obtained from parents (proxy 
assessment) .Version was translated into russian language and adapted. HUI cur-
rently consists of two systems: HUI Mark 2 and HUI Mark 3. Each HUI2 and HUI3 
classification system consists of attributes (domains) of health and 3 to 6 levels of 
functional ability/disability within each attribute and is very responsive to changes 
and to highlight avenues of additional study. Single-attribute utility scores and 
multi-attribute utility scores evaluated corresponding to each system, ranges from 
0 to 1. Results: Mean Mark 2 has a tendency to increase from 0,85 in children 
5 years to 0,95 in children 15 years with reduction in 6 years (0,80), 12 years (0,85) 
and 16 years (0,85). Same tendency was observed in Mark 3: 6 years- 0,75; 12 years- 
0,75; 16 years- 0,77 ConClusions: Decrease of quality of life in above mentioned 
ages is a result of unadequate treatment in children living in some regions of CIS 
and severe complications of CF in older children also.
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imPACt of ‘oN’ AND ‘off’ time
Kerr C1, Howard C.E1, Johnston K2, Smith H.T.3, Lloyd E3, Cooper J.A3, McIntosh E.4,  
Lloyd A.J.1
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objeCtives: Diurnal variation in symptoms and functioning is a feature of 
Parkinson’s disease, referred to as ‘on’ and ‘off time’. Typically patient reported 
outcomes (PROs) don’t capture this variability or its value, instead requesting par-
ticipants report over the last day or week. This study evaluated the impact and value 
of ‘on’ and ‘off time’ for people with Parkinson’s (PwP) by assessing their HRQL and 
strength of preference. Methods: PwP from UK, Spain, France and Italy (n= 305), 
experiencing ≥ 2 hours ‘off time’ daily, completed EQ-5D-5L assessments for ‘on’ 
and ‘off time’ that day, followed by a discrete choice experiment (DCE) evaluating 5 
treatment attributes: duration of ‘on time’; quality of ‘off time’; predictability of ‘off 
time’; feelings of anxiety/depression, and dosing frequency. The DCE was informed 
by qualitative work with patients (n= 20), carers (n= 6) and health professionals (n= 6) 
in UK and Spain and employed an orthogonal, factorial, fold-over design. Analysis 
used the mixed-logit model and effects coding of categorical levels (predictability of 
off-time attribute). Results: Mean EQ-5D utility values were significantly lower for 
‘off time’ (0.37, 95%CI: 0.33-0.40) than ‘on time’ (0.60, 95%CI: 0.57-0.62). All attributes 
were significant drivers of treatment choice. PwP valued increased duration of ‘on 
time’ (per hour per day: OR= 1.40, 95%CI 1.31-1.45) and predictability of ‘off time’ 
most highly (predictability to within 30 minutes of symptoms returning: OR= 1.42, 
95%CI 1.15-1.57). High disutility was reported for substantial unpredictablility of ‘off 
time’ (OR= 0.67, 95%CI 0.49-0.91). ConClusions: Important differences in quality 
of life between ‘on’ and ‘off time’ were found which could be missed by standard 
PRO assessment, including the relative value that PwP placed on increased dura-
tion of ‘on time’ and predictability of ‘off time’. Assessments and interpretation of 
outcomes in Parkinson’s should consider diurnal variation. Capturing this variation 
and its value may require modifications to PRO design. [Study HO-11-802]
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objeCtives: Albeit effectiveness of subcutaneous treatments for Multiple 
Sclerosis (MS) has been demonstrated, adverse reactions and pain may entail prob-
lems regarding treatment satisfaction and continuity. This study aims to adapt 
and validate the Spanish version of the “Multiple Sclerosis Treatment Concerns 
Questionnaire-MSTCQ”, which evaluates satisfaction with the injection device (ID) 
in 4 dimensions: Injection system (A), Side-effects (B) (flu-like symptoms, reactions, 
and satisfaction), Treatment experience (C) and Benefits (D). Methods: Two Stages: 
1) Cultural adaptation: Forward-backward translation and expert (n= 6) and patient 
(n= 30) panels; 2) Validation: Observational, cross-sectional, multicenter study. A 
total of 143 adult patients suffering from MS and using an ID were evaluated. Tools 
employed: MSTCQ, Patient-Reported Indices for Multiple Sclerosis (PRIMUS), Treatment 
Satisfaction Questionnaire for Medication (TSQM), Morisky Green and Patient Injection 
Site Reaction (ISR) and Injection Site Pain (ISP). Psychometric properties: Feasibility 
(% valid cases and ground/ceiling effects); Reliability (Cronbach α ) and test-retest 
(41 patients, Intraclass Correlation Coefficient, ICC); as well as construct (Factorial 
analysis of dimensions A and B, FA) and convergent (Spearman MSTCQ vs. TSQM) 
validity. Results: Mean age(SD) in cases was 41,94(10,47) years, 63% female, 88,11% 
suffering from Relapsing-Remitting MS. MSTCQ feasibility was adequate (missing 
0%-2,80%). High internal consistency, total score (A+B) α = 0, 89, by dimensions α (A, 
B and C): 0,76, 0,89 and 0,92, respectively. Furthermore, a concordance was found 
between total (ICC= 0, 98) and by dimensions ICC (A, B and C) scores: 0,82, 0,97 and 
0,89, respectively. The FA confirms dimensions A and B from the original question-
naire. Lastly, the association between total and by dimensions scores, from MSTCQ 
and TSQM was, overall, moderately strong (Rho between-0, 74, y 0, 42) and significant 
isfaction and preferences for MS treatments. Bibliographic references were hand 
searched. English or Spanish studies published between January 2007 and January 
2013 were selected. Results: A total of 398 citations were identified; 12 studies 
accomplished the inclusion criteria. Six referred to PROs and treatment costs; 4 
analyzed satisfaction with disease-modifying therapies (DMTs) and 2 assessed pref-
erences for treatment attributes. An increased adherence and persistence on DMTs 
was associated to higher pharmacy costs and to better clinical outcomes [lower 
relapse risk (OR= 0.71 CI 95%, 0.59-0.85); decreased MS hospitalizations (OR= 0.63, 
CI 95%, 0.47 – 0.83)] leading to a cost reduction of up to 22% patient/year. DMT 
adherent patients had a significantly lower rate of severe relapses (12.5% vs. 19.5%; 
p= 0.0200), lower MS-related or all-causes medical (7.6% vs. 12.5%; p= 0.0447 and 
11.2% vs. 20.0%; p= 0.0027) and emergency visits (8.9% vs. 15.0%; p= 0.0215 and 34.6% 
vs. 43.5%; p= 0.0305) than non-adherent. MS-related and all-cause inpatient costs 
(354.77±2.485.03 vs. 853.13±3,635.48; p= 0.0270 and 648.71±3,753.74 vs. 62.51±265.23; 
p= 0.0018) as well as emergency visit costs (46.46±255.94 vs. 1,740.88±6,127.27; 
p= 0.0076 and 147.82±430.79 vs. 242.42±592.96; p= 0.0044) were significantly lower 
in adherent patients. Self-injection [Visual Analogue Scale (VAS) mean 6.9; range 
0-10] render higher treatment satisfaction. Slower disability progression (efficacy) 
was the most preferred attribute (p< 0,001). Newly developed electronic devices 
that allow adjusting injection settings as well as adherence objective monitoring 
appeal more to patients (VAS mean 7.7; range 0-10) than more traditional methods 
of administration. ConClusions: MS studies assessing adherence and costs are 
scarce. Treatments and devices better tailored to patients’ needs improve adherence, 
enhance clinical outcomes and procure a reduction on MS costs.
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objeCtives: To present health state values (QALY weights) for multiple scle-
rosis (MS) health states using data from a prospective, longitudinal, cohort 
study. Methods: Data from a large UK cohort study for MS, the South West Impact 
of MS (SWIMS) Study, were used for analysis. SWIMS data comprise six-monthly 
self-report assessments, including EQ-5D and SF-36 health status measures, and 
data on relapse frequency/severity. Self-report data is supplemented with data 
from clinician assessment of disability using the EDSS. Health state valuation data 
are sourced from published UK tariffs (EQ-5D and SF-6D) to present values for MS 
against EDSS, relapse characteristics, and against other disease related characteris-
tics. Results: Analyses of SWIMS data included 1,441 respondents, over an average 
of 8 time-points. Findings on health state values show a health profile that wors-
ens by disease progression, against EDSS stages, using both the EQ-5D and SF-6D 
methods. Health state values estimated from EQ-5D data range from 0.76 at EDSS 
stage 1.0 to 0.03 at EDSS stage 8, with lower values seen for progressive MS. Values 
estimated from SF-36 data reflect the narrower range of values possible on the SF6D 
tariffs, with values from 0.7 to 0.53 across EDSS stages 1.0 to 8. Findings demonstrate 
impact on health state values due to relapse events, with this impact reported at 
0.08 using the EQ-5D and at 0.05 using the SF-6D. The impact of relapse frequency, 
severity and endurance on health has also been assessed. ConClusions: This 
study presents health state valuation data derived from a high quality longitudinal 
cohort study, including values (QALY weights) for features/characteristics of relapse 
events in people with MS. This data can support improvements in the conduct of 
cost-effectiveness analyses of treatments for MS, and can be helpful in a general 
health policy context.
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CAregiVer bUrDeN iN frAgile x syNDrome As A fUNCtioN of A heAlth 
stAte Utility iNDex iN the UNiteD stAtes
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objeCtives: To assess the association between burden experienced by caregivers 
of patients with fragile X syndrome (FXS) in the United States and a health state 
utilities index derived from the Aberrant Behavior Checklist-Community (ABC-
C). Methods: A total of 340 US caregivers of children with FXS completed a ques-
tionnaire that captured information on FXS-related burden (i.e., specialist visits, 
medical tests, medications, financial burden, employment status, paid and unpaid 
caregiving, caregiver injuries, and mental health). Using the ABC-Utility Index 
(ABC-UI), an estimate of health-related quality-of-life derived from the ABC-C, five 
utility index categories were created: very low (0.00–0.33); low (0.34–0.66); moderate 
(0.67–0.77); high (0.78–0.89); and very high (0.90–1.00). After controlling for sex, age, 
overall ability level, and income, multivariable regression models documented the 
association between utility score and the nine burden-related outcomes. Results: 
Respondents (283 with FXS male child; 57 with FXS female child) were mostly female 
(91%), Caucasian (92%), and married (84%), with mean age of 50 years. Approximately 
2% of individuals with FXS were in the very low utility category, 30.6% low, 27.1% 
moderate, 37.6% high, and 2.6% very high. The mean utility score was 0.71. Females 
with FXS and adults ≥ 18 years had higher health utilities. Results from regression 
models indicate that increasing utility values reduced the likelihood of ≥ 5 (vs. < 5) 
specialist visits (b= -4.583; p< 0.001) and ≥ 2 (vs. 0 or 1) prescription medications 
used (b= -4.517; p< .001). Similarly, increasing utility score was associated with a 
decreased likelihood of ≥ 8 (vs. < 8) hours of unpaid caregiving (b= -2.723; p= 0.003), 
≥ 1 (vs. 0 or 1) caregiver injuries (b= -7.540; p< 0.001), and ≥ 1 (vs. 0) mental health 
provider visits (b= -2.613; p= 0.002). ConClusions: The ABC-UI appears to function 
well as a health-related quality-of-life indicator in individuals with FXS. Among 
caregivers of patients with FXS in the US, significant differences in burden exist 
across health state utilities.
